Skip to main content
SpringerLink
Log in

Neuroendocrine tumours of the lung

  • Chapter
Management of Rare Adult Tumours

  • 1013 Accesses

Abstract

Neuroendocrine tumours of the lung (NETL) are rare, representing some 20 % of lung tumours. This term groups different entities, covering a wide histological spectrum: typical (TC) and atypical (AC) carcinoid tumours, large cell neuroendocrine carcinomas (LCNEC) as well as small cell carcinomas (SCLC), the frequency of which is high (15% of lung tumours and nearly 80% of neuroendocrine tumours of the lung), the latter not described in this chapter. The clinical presentation and progressive profile of NETL are different and reflect a growing aggressiveness. The knowledge of the oncogenesis and natural history of these tumours has greatly evolved in recent years and the histological criteria that allow their individualisation have been refined; however, their rarity has as yet prevented the definition of an optimal treatment. Nonetheless, encouraging therapeutic prospects are creating renewed interest in clinical research on these little-known tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anbazhagan R, Tihan T, Bornmann DM et al. (1999) Classification of small cell lung cancer and pulmonary carcinoid by gene expression profile. Cancer Res 59: 5119–22.

    CAS  PubMed  Google Scholar 

  2. Anthony L, Chester M, Michael S et al. (2006) Phase II open-label clinical trial of vatalanib (PTK/2K) in patients with progressive neuroendocrine cancer. ASCO Meeting Abstracts 24: 4044

    Google Scholar 

  3. Asamura H, Kameya T, Matsuno Y et al. (2006) Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24(1): 70–5

    Article  PubMed  Google Scholar 

  4. Battafarano RJ, Fernandez, FG, Ritter J (2005) Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer. JThorac Cardiovasc Surg 130(1): 166–71

    Article  Google Scholar 

  5. Bertoletti L, Elleuch R, Kaczmarek D et al. (2006) Bronchoscopic cryotherapy treatment of isolated endoluminal typical carcinoid tumour. Chest 130: 1405–11

    Article  PubMed  Google Scholar 

  6. Cardillo G, Sera F, Di Martino M et al. (2004). Bronchial carcinoid tumours: nodal status and long-term survival after resection. Ann Thorac Surg 77: 1781–5

    Article  PubMed  Google Scholar 

  7. Daddi N, Ferolla P, Urbani M et al. (2004) Surgical treatment of neuroendocrine tumours of the lung. Eur J Cardiothorac Surg 26: 813–7

    Article  PubMed  Google Scholar 

  8. Daniels CE, Lowe VJ, Aubry MC et al. (2007). The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumours presenting as pulmonary nodules. Chest 131: 255–260.

    Article  PubMed  Google Scholar 

  9. Di Bartolomeo M, Bajetta E, Buzzoni R et al. (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumours. A study by the Italian Trials in Medical Oncology Group. Cancer 77: 402–8

    Article  PubMed  Google Scholar 

  10. Ekeblad S, Sundin A, Janson ET et al. (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumours. Clin Cancer Res 13: 2986–91

    Article  CAS  PubMed  Google Scholar 

  11. Faggiano A, Sabourin JC, Ducreux M et al. (2007) Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas. Diagnostic and prognostic features. Cancer 110(2): 265–74

    Article  CAS  PubMed  Google Scholar 

  12. Fernandez FG, Battafarano RJ (2006) Large cell neuroendocrine carcinoma of the lung. Cancer Control 13: 270–5

    PubMed  Google Scholar 

  13. Filosso PL, Rena O, Donati G et al. (2002). Bronchial carcinoid tumours: surgical management and long-term outcome. J Thorac Cardiovasc Surg 123: 303–9

    Article  PubMed  Google Scholar 

  14. Fink G, Krelbaum T, Yellin A et al. (2001) Pulmonary carcinoid: presentation, diagnosis and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 119: 1647–51

    Article  CAS  PubMed  Google Scholar 

  15. Garcia-Yuste M, Matilla JM, Cueto A et al. (2007) Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J CardioThorac Surg 31:192–7

    Article  PubMed  Google Scholar 

  16. Granberg D, Eriksson B, Wilander E (2001) Experience in treatment of metastatic pulmonary carcinoid tumours. Ann Oncol 12: 1383–91

    Article  CAS  PubMed  Google Scholar 

  17. Hage R, Brutel de la Rivière A, Seldenrijk CA, van den Bosch JMM (2003) Update in pulmonary carcinoid tumours: a review article. Ann Surg Oncol 10: 697–704

    Article  CAS  PubMed  Google Scholar 

  18. Hobday TJ, Rubin J, Holen K et al. (2007) MCO44h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumours (NET): A Phase II Consortium (P2C) study. ASCO Meeting Abstracts 25: 4504

    Google Scholar 

  19. Iyoda A, Hiroshima K, Moriya Y et al. (2006) Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non small cell carcinoma. JThorac Cardiovasc Surg 132(2): 312–5

    Article  Google Scholar 

  20. Kulke MH, Stuart K, Earle CC et al. (2006) A phase II study of temzolomide and bavacizumab in patients with advanced neuroendocrine tumours. ASCO Meeting Abstracts 24: 4044

    Google Scholar 

  21. Kulke MH, Lenz HJ, Meropol NJ et al. (2008) Activity of sufitinib in patients with advanced neuroendocrine tumours. J Clin Oncol 26: 3403–10

    Article  CAS  PubMed  Google Scholar 

  22. Kunz PL, Kuo T, Kaiser HL et al. (2008) A phase II study of capecitabine, oxaliplatine and bevacizumab for metastatic or unresectable neuroendocrine tumours: Preliminary results. ASCO Meeting Abstracts 26: 15502

    Google Scholar 

  23. Lim E, Yap YK, De Stavola BL et al. (2005). The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumours. J Thorac Cardiovasc Surg 130(4): 969–72

    Article  PubMed  Google Scholar 

  24. Luckraz H, Amer K, Thomas L et al. (2006). Long-term outcome of bronchoscopically resected endobronchial typical carcinoid tumours. J Thorac Cardiovasc Surg 132: 13–5

    Article  Google Scholar 

  25. Marom EM, Sarvis S, Herndon JE (2002) Lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 223: 453–9

    Article  PubMed  Google Scholar 

  26. Martini N, Zaman M, Bains M et al. (1994) Treatment and prognosis in bronchial carcinoid involving regional lymph nodes. J Thorac Cardiovasc Surg 107: 1–7

    CAS  PubMed  Google Scholar 

  27. Mezzetti M, Raveglia F, Panigalli T et al. (2003) Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification. Ann Thorac Surg 76: 1838–42

    Article  PubMed  Google Scholar 

  28. Mitry E, Baudin E, Ducreux M et al. (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81: 1351–5

    Article  CAS  PubMed  Google Scholar 

  29. Moertel CG, Hanley JA (1979) Combination chemotherapy trials in metastatic carcinoid tumour and the malignant carcinoid syndrome. Cancer Clin Trials 2: 327–34

    CAS  PubMed  Google Scholar 

  30. Nobels FR, Kwekkeboom DJ, Coopmans W et al. (1997) Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endoc Metabol 82: 2622–8

    Article  CAS  Google Scholar 

  31. Oliveira AM, Tozelaar HD, Wentzlaff KA (2001) Familiar pulmonary carcinoid tumours. Cancer 91: 2104–9

    Article  CAS  PubMed  Google Scholar 

  32. Paci M, Cavazza A, Annessi V et al. (2004). Large cell neuroendocrine carcinoma of the lung: A 10-year clinicopathologic retrospective study. Ann Thorac Surg 77: 1163–7

    Article  PubMed  Google Scholar 

  33. Phan AT, Wang L, Xie K et al. (2008). Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma. ASCO Meeting Abstracts 24: 4091

    Google Scholar 

  34. Rosado de Christenson M, Abbott G, Kirejezyk W (1999) Thoracic carcinoids: radiologic-pathologic correlation. Radiographics 19: 707–36

    CAS  PubMed  Google Scholar 

  35. Rossi G, Cavazza A, Marchioni A et al. (2006). Role of chemotherapy and receptor tyrosyne kinases KIT, PDGFR alpha, PDGFR béta, and MET in large cell neuroendocrine carcinoma of the lung. J Clin Oncol 23(34): 8774–85

    Article  Google Scholar 

  36. Schupak KD, Wallner KE (1991) The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumours. Int J Radiat Oncol Biol Phys 20: 489–95

    Article  CAS  PubMed  Google Scholar 

  37. Scott WJ (2003) Surgical treatment of other bronchial tumours. Chest Surg Clin North Am 13: 111–28

    Article  Google Scholar 

  38. Skov BG, Krasnik M, Lantuejoul S et al. (2008). Reclassification of neuroendocrine tumours improves the separation of carcinoids and the prediction of survival. J Thorac Oncol 12: 1410–5

    Article  Google Scholar 

  39. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH (2002) Pulmonary neuroendocrine tumours: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 37: 127–35

    Article  PubMed  Google Scholar 

  40. Squerzanti A, Basteri V, Antinolfi G (2002) Bronchial carcinoid tumours: clinical and radiological correlation. Radiol Med 104: 273–84

    PubMed  Google Scholar 

  41. Sun W, Lipsitz S, Catalano P et al., Eastern Cooperative Oncology Group (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumours: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 23: 4897–904

    Article  CAS  PubMed  Google Scholar 

  42. Takei H, Asamura H, Maeshima A et al. (2002) Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 124(2): 285–92

    Article  PubMed  Google Scholar 

  43. Travis WD, Rush W, Flieder DB et al. (1998). Survival analysis of 200 pulmonary neuroendocrine tumours with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Pathol 22(8): 934–44

    Article  CAS  Google Scholar 

  44. Venook AP, Ko AH, Tempero MA et al. (2008). Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumours. ASCO Meeting Abstracts 26: 15545

    Google Scholar 

  45. Veronesi G, Morandi U, Alloisio M et al. (2006) Large cell carcinoma of the lung: A retrospective analysis of 144 surgical cases. Lung Cancer 53: 111–5

    Article  PubMed  Google Scholar 

  46. Wirth LJ, Carter MR, Jänne PA, Johnson BE (2004) Outcome of patients with pulmonary carcinoid tumours receiving chemotherapy or chemoradiotherapy. Lung Cancer 44: 213–20

    Article  PubMed  Google Scholar 

  47. Yamazaki S, Sekine I, Matsuno Y et al. (2005) Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 49(2): 217–23

    Article  PubMed  Google Scholar 

  48. Yao JC, Phan A, Hoff PM et al. (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumour: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26: 1316–23

    Article  CAS  PubMed  Google Scholar 

  49. Yao JC, Hassan M, Phan A et al. (2008) One hundred years after “carcinoid”: Epidemiology and prognostic factors for neuroendocine tumours in 35,852 cases in the United States. J Clin Oncol 26: 3063–72

    Article  PubMed  Google Scholar 

  50. Yao JC, Phan AT, Chang DZ et al. (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumours: results of a phase II study. J Clin Oncol 26: 4311–7

    Article  PubMed  Google Scholar 

Download references

Authors
  1. A. Bonnichon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Le Floch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Rivière
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Margery
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Vaylet
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000, Créteil Cedex, France

    Yazid Belkacémi MD PhD (Professor Radiation Oncology, Deputy Head of the Department of Radiation Oncology) (Professor Radiation Oncology, Deputy Head of the Department of Radiation Oncology)

  2. Centre hospitalier universitaire Vaudoir, Rue du Bugnon, CH-1011, Lausanne, Switzerland

    René-Olivier Mirimanoff MD (Professeur Radiation Oncology, Head of the Department of Radiation Oncology) & Mahmut Ozsahin MD PhD (Associate Professor in the Department of Radiation Oncology) (Professeur Radiation Oncology, Head of the Department of Radiation Oncology) &  (Associate Professor in the Department of Radiation Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Bonnichon, A., Le Floch, H., Rivière, F., Margery, J., Vaylet, F. (2009). Neuroendocrine tumours of the lung. In: Belkacémi, Y., Mirimanoff, RO., Ozsahin, M. (eds) Management of Rare Adult Tumours. Springer, Paris. https://doi.org/10.1007/978-2-287-92246-6_48

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-92246-6_48

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-92245-9

  • Online ISBN: 978-2-287-92246-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation